Cargando…
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738605/ https://www.ncbi.nlm.nih.gov/pubmed/33344227 http://dx.doi.org/10.3389/fonc.2020.566315 |
_version_ | 1783623153689296896 |
---|---|
author | Merlino, Dante J. Johnson, Jennifer M. Tuluc, Madalina Gargano, Stacey Stapp, Robert Harshyne, Larry Leiby, Benjamin E. Flanders, Adam Zinner, Ralph Axelrod, Rita Curry, Joseph Cognetti, David M. Mannion, Kyle Kim, Young J. Rodeck, Ulrich Argiris, Athanassios Luginbuhl, Adam J. |
author_facet | Merlino, Dante J. Johnson, Jennifer M. Tuluc, Madalina Gargano, Stacey Stapp, Robert Harshyne, Larry Leiby, Benjamin E. Flanders, Adam Zinner, Ralph Axelrod, Rita Curry, Joseph Cognetti, David M. Mannion, Kyle Kim, Young J. Rodeck, Ulrich Argiris, Athanassios Luginbuhl, Adam J. |
author_sort | Merlino, Dante J. |
collection | PubMed |
description | PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of involvement (primary tumor, lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic treatment effect. PATIENTS AND METHODS: Forty-four patients enrolled in trial NCT03238365 were treated with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as determined by random assignment, followed by surgery on day 31. Radiographic volumetric response (RVR) was defined as percent change in tumor volume from pretreatment to posttreatment CT scan. Responders were defined as those with a 10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic inflammation divided by total tumor area. RESULTS: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited discordant PTE between primary sites and LN. In four patients with widely discordant adjacent LN, increased PTE was associated with increased infiltration of tumor CD8(+) T cells and CD163(+) macrophages, whereas stromal regulatory T cells were associated with low nodal PTE. RVR correlated with PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN (slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders had moderate (n = 12) or complete (n = 3) PTE. CONCLUSION: Nivolumab often induces discordant treatment effects between primary tumor sites and metastatic lymph nodes within subjects. This treatment discordance was also demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup. Finally, although these data were generated by a relatively small population size, our data support the use of early radiographic response to assess immunotherapy treatment effect in HNSCC. |
format | Online Article Text |
id | pubmed-7738605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77386052020-12-17 Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect Merlino, Dante J. Johnson, Jennifer M. Tuluc, Madalina Gargano, Stacey Stapp, Robert Harshyne, Larry Leiby, Benjamin E. Flanders, Adam Zinner, Ralph Axelrod, Rita Curry, Joseph Cognetti, David M. Mannion, Kyle Kim, Young J. Rodeck, Ulrich Argiris, Athanassios Luginbuhl, Adam J. Front Oncol Oncology PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of involvement (primary tumor, lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic treatment effect. PATIENTS AND METHODS: Forty-four patients enrolled in trial NCT03238365 were treated with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as determined by random assignment, followed by surgery on day 31. Radiographic volumetric response (RVR) was defined as percent change in tumor volume from pretreatment to posttreatment CT scan. Responders were defined as those with a 10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic inflammation divided by total tumor area. RESULTS: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited discordant PTE between primary sites and LN. In four patients with widely discordant adjacent LN, increased PTE was associated with increased infiltration of tumor CD8(+) T cells and CD163(+) macrophages, whereas stromal regulatory T cells were associated with low nodal PTE. RVR correlated with PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN (slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders had moderate (n = 12) or complete (n = 3) PTE. CONCLUSION: Nivolumab often induces discordant treatment effects between primary tumor sites and metastatic lymph nodes within subjects. This treatment discordance was also demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup. Finally, although these data were generated by a relatively small population size, our data support the use of early radiographic response to assess immunotherapy treatment effect in HNSCC. Frontiers Media S.A. 2020-12-02 /pmc/articles/PMC7738605/ /pubmed/33344227 http://dx.doi.org/10.3389/fonc.2020.566315 Text en Copyright © 2020 Merlino, Johnson, Tuluc, Gargano, Stapp, Harshyne, Leiby, Flanders, Zinner, Axelrod, Curry, Cognetti, Mannion, Kim, Rodeck, Argiris and Luginbuhl http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Merlino, Dante J. Johnson, Jennifer M. Tuluc, Madalina Gargano, Stacey Stapp, Robert Harshyne, Larry Leiby, Benjamin E. Flanders, Adam Zinner, Ralph Axelrod, Rita Curry, Joseph Cognetti, David M. Mannion, Kyle Kim, Young J. Rodeck, Ulrich Argiris, Athanassios Luginbuhl, Adam J. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect |
title | Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect |
title_full | Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect |
title_fullStr | Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect |
title_full_unstemmed | Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect |
title_short | Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect |
title_sort | discordant responses between primary head and neck tumors and nodal metastases treated with neoadjuvant nivolumab: correlation of radiographic and pathologic treatment effect |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738605/ https://www.ncbi.nlm.nih.gov/pubmed/33344227 http://dx.doi.org/10.3389/fonc.2020.566315 |
work_keys_str_mv | AT merlinodantej discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT johnsonjenniferm discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT tulucmadalina discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT garganostacey discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT stapprobert discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT harshynelarry discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT leibybenjamine discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT flandersadam discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT zinnerralph discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT axelrodrita discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT curryjoseph discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT cognettidavidm discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT mannionkyle discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT kimyoungj discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT rodeckulrich discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT argirisathanassios discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect AT luginbuhladamj discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect |